PharmaShots | Incisive News in 3 Shots

Subscribe Now

Cytokine Release Syndrome

Novartis' Ilaris (canakinumab) Fails to Meet its Primary Endpoints in P-lll Study for COVID-19 Pneumonia and CRS

Novartis' Ilaris (canakinumab) Fails to Meet its Primary Endpoints in P-lll Study for COVID-19 Pneumonia and CRS

November 9, 2020

I-Mab to Initiate the Development of TJM2 for Treating Cytokine Release Syndrome Associated with COVID-19

I-Mab to Initiate the Development of TJM2 for Treating Cytokine Release Syndrome Associated with COVID-19

March 13, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us